A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/352 (2006.01) A61K 31/135 (2006.01) A61K 31/165 (2006.01) A61K 31/335 (2006.01) A61K 31/35 (2006.01) A61K 31/70 (2006.01) A61K 45/06 (2006.01) A61P 35/00 (2006.01) G01N 33/574 (2006.01)
Patent
CA 2399402
CYP1B1 proteins and their role in metabolising or inactivating anti-cancer drugs is disclosed, together with compositions for treating cancer comprising a substance capable of inhibiting CYP1B1 protein and an anti-cancer drug (e.g. docetaxel, paclitaxel, flutamide, tamoxifen, mitoxantrone, doxorubicin or daunomycin).
L'invention porte sur les protéines CYP1B1 et leur rôle pour métaboliser et/ou désactiver certains médicaments anticancéreux, sur des compositions de traitement du cancer contenant une substance capable d'inhiber la protéine CYP1B1, et sur un médicament anticancéreux (par exemple: docétaxel, paclitaxel, flutamide, tamoxifène, mitoxantrone, doxorubicine ou daunomycine).
Mcfadyen Morag
Melvin William Thomas
Murray Graeme Ian
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
The University Court Of The University Of Aberdeen
LandOfFree
Use of cyp1b1 inhibitors for treating cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of cyp1b1 inhibitors for treating cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of cyp1b1 inhibitors for treating cancer will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2043747